久久久国产一区二区_欧美在线小视频_高清一区二区三区_久久综合久久久_成人久久久久久久久_亚洲精品视

上海非利加實(shí)業(yè)有限公司Logo

熱門詞: 進(jìn)口電動(dòng)溫度調(diào)節(jié)閥結(jié)構(gòu)圖|進(jìn)口電動(dòng)溫度調(diào)節(jié)閥數(shù)據(jù)表進(jìn)口電動(dòng)高溫調(diào)節(jié)閥-德國進(jìn)口電動(dòng)高溫法蘭調(diào)節(jié)閥進(jìn)口電動(dòng)蒸汽調(diào)節(jié)閥-德國進(jìn)口電動(dòng)蒸汽調(diào)節(jié)閥

當(dāng)前位置: 首頁 > 所有品牌 > MicuRx
MicuRx
MicuRx MicuRx

MicuRx 盟科醫(yī)藥  
MicuRx 致力于發(fā)現(xiàn)和開發(fā)治療由耐藥菌引起感染的新型抗生素。該公司將其美國研發(fā)團(tuán)隊(duì)的豐富經(jīng)驗(yàn)與中國高品質(zhì)、高經(jīng)濟(jì)效益的藥物研發(fā)優(yōu)勢(shì)相結(jié)合,逐漸建立起一個(gè)治療各類耐藥革蘭氏陽性和陰性菌新藥的平臺(tái)。該公司在美國加州硅谷和中國張江設(shè)有研發(fā)實(shí)驗(yàn)室。MicuRx 在首輪風(fēng)險(xiǎn)融資中從 Morningside Group 和 Devon Park Bioventures  募集了1200萬美元。

 
盟科醫(yī)藥技術(shù)(上海)有限公司成立于2007年7月,致力于開發(fā)擁有自主知識(shí)產(chǎn)權(quán)的新一代抗菌藥物,以解決日益嚴(yán)重的、由于耐藥菌引起的感染,并在未來實(shí)現(xiàn)其工業(yè)生產(chǎn)和商業(yè)化。
經(jīng)過三年多的高效運(yùn)轉(zhuǎn),公司自主研發(fā)的第一個(gè)候選1.1類新藥MRX-I,其前期研究得到了國家“十一五重大新藥創(chuàng)制”的一定支持,現(xiàn)已完成了前期藥學(xué),毒理和生產(chǎn)工藝的研究,于2009年在中國申報(bào)臨床試驗(yàn)(IND),并已取得中國食品藥品監(jiān)督管理局進(jìn)行臨床試驗(yàn)的批文,已經(jīng)進(jìn)入一期人體臨床試驗(yàn)。該1.1類新藥有望于2015年前后在中、美同時(shí)上市,預(yù)期全球市場(chǎng)可達(dá)十億美元。
   


MicuRx discovers and develops novel antibiotics to combat drug resistant bacterial infections. Founded in 2007, MicuRx employs a hybrid U.S./China business model to capitalize on the global opportunities afforded by U.S. research and development coupled with the high-quality, cost-efficient infrastructure and scientific resources available in China. This hybrid business model enables MicuRx to implement an accelerated global development strategy with a goal of completing Phase II trials for its drug candidates in both the United States and China.

Infections due to multi-drug resistant bacteria have become a major threat to public health. In particular, methicillin-resistant Staphylococcus aureus (MRSA) has quickly spread from the hospital setting into the community and vancomycin-resistant enterococci (VRE) now represents at least 30% of all hospital enterococci infections. Importantly, bacteria continue to evolve and new strains of bacteria are resistant to even the newest antibiotics.

Using its proprietary drug discovery platform, MicuRx has generated a broad pipeline of antimicrobial agents to treat Gram-positive, Gram-negative and fungal infections. MicuRx's lead drug candidate is MRX-I, a next-generation oxazolidinone antibiotic with a superior therapeutic window projected to offer significant clinical differences over existing drugs. MicuRx filed its first Investigational New Drug (IND) application in China and received "Special Review" status from the State Food and Drug Administration.

In addition to its internal pipeline, MicuRx and Pfizer have entered a collaboration agreement to discover and develop new therapeutic agents to treat drug-resistant tuberculosis. All collaboration research will be conducted at the ZhangJiang High-Tech Park in Shanghai, China.

關(guān)于我們客戶服務(wù)產(chǎn)品分類法律聲明
主站蜘蛛池模板: 日本孕妇与黑人xxxxxx | 国产美女一级毛片 | 国产精品3p视频 | 欧美亚洲综合另类 | 亚洲三级在线视频 | 日韩影音| 日韩欧美高清一区 | 日韩 亚洲 制服 欧美 综合 | 亚洲国产精品成人久久 | 在线观看欧美国产 | 久久久久久综合一区中文字幕 | 欧美 亚洲 一区 | 国产精品 视频一区 二区三区 | 色婷婷综合在线 | 精品一区二区三区在线成人 | 黑人粗又大 | 青青国产成人久久激情91麻豆 | 国产高清美女一级a毛片久久 | 91专区 | 亚洲欧美日韩高清综合678 | 黄色一级视频免费 | 成人国产精品视频 | 日韩αv | 欧美一级在线 | 日韩系列第一页 | 91区国产 | 欧美日韩大片 | 青青草原国产一区二区 | 亚洲成人一区二区 | 日产精品久久久一区二区 | 91在线视频一区 | 亚洲欧美日韩成人 | 美女视频一区二区 | 亚洲精品免费观看 | 欧美日韩中出 | 久久成人国产精品二三区 | 一区二区精品在线 | 国产综合成人久久大片91 | 国产精品久久久久9999 | 鸣人x钢手 | 日韩另类在线 |